Valproic acid induced encephalopathy – 19 new cases in Germany from 1994 to 2003 – A side effect associated to VPA-therapy not only in young children  by Gerstner, Thorsten et al.
Seizure (2006) 15, 443—448
www.elsevier.com/locate/yseizValproic acid induced encephalopathy — 19 new
cases in Germany from 1994 to 2003 — A side
effect associated to VPA-therapy not only
in young children
Thorsten Gerstner a,*, Deike Buesing a, Elke Longin a,
Claudia Bendl a, Dieter Wenzel b, Brigitte Scheid b, Gisela Goetze b,
Alfons Macke b, Gerhard Lippert b, Wolfgang Klostermann b,
Geert Mayer b, Regine Augspach-Hofmann b, Sabine Fitzek b,
Carl-Albrecht Haensch b, Markus Reuland b, Stephan A. Koenig aaUniversity Children’s Hospital Mannheim, Neuropediatric Unit,
Theodor-Kutzer-Ufer 1-3, 69167 Mannheim, Germany
bVPA-induced Side Effects Study Group: Children’s Hospital Erlangen, Hamburg, Bruckmuehl,
Hagen, Olpe, General Hospital Neukirchen, University Children’s Hospital Jena, Helios-Klinikum
Wuppertal, Neuwied, University Hospital Halle-Wittenberg, Germany
Received 23 January 2006; received in revised form 10 May 2006; accepted 23 May 2006KEYWORDS
Valproic acid;
Side effects;
Encephalopathy;
Ammonia
Summary Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually
well-tolerated. Rare serious complications may occur in some patients, including
haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity
and VPA-induced encephalopathy. The typical signs of VPA-induced encephalopathy
are impaired consciousness, sometimes marked EEG background slowing, increased
seizure frequency, with or without hyperammonemia.
There is still no proof of causative effect of VPA in patients with encephalopathy,
but only of an association with an assumed causal relation. We report 19 patients with
VPA-associated encephalopathy in Germany from the years 1994 to 2003, none of
whom had been published previously.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Sodium valproate (VPA) is a branched-chain fatty
acid that is widely used in the therapy of epilepsy.* Corresponding author.
1059-1311/$ — see front matter # 2006 British Epilepsy Association
doi:10.1016/j.seizure.2006.05.007The anticonvulsive action of VPA has been demon-
strated to be due to a combined pharmacological
effect of increased g-amino-butyric acid (GABA)
levels1 inhibition of N-methyl-D-aspartat (NMDA). Published by Elsevier Ltd. All rights reserved.
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Table 1 VPA-induced encephalopathies with hyperammonemia
Age
(year)
Sex Underlying
disease
Retar-ded EEG VPA-level
(mg/l)
ASAT U/l,
ALAT U/l,
Ammonia
(gmol/l)
(11—55)
Add. AED Add.
disease
Outcome
1 65 M Cerebri
med. infarct
+ delta-focus 84.6 Normal 150 — CHD,
hypertonia
Recovery after
withdrawal of VPA
2 4.6 F Focal epilepsy — Generalized
d-activity
170 Normal 208 ETH — Recovery after
withdrawal of VPA
3 1.9 F Absence-epilepsy — Background
slowing
a 38/33 111 — Enteritis Recovery after
withdrawal of VPA
4 0.8 M MELAS + Gen. d-activity a 4,— 258 PB, SUL,
LTG,CL
Susp.
of amino-
acid
metabolic
disease
Recovery after
withdrawal of VPA
5 2.6 M Pseudo-Lennox-
Gastaut
+ Background
slowing
— 77, 36 159 TPM, ETH Anaemia— Recovery after
withdrawal of VPA
6 16 F IGE — Background
slowing
74.5 Normal 261 — — Recovery after
withdrawal of VPA
ALAT, alaninaminotransferase; ASAT, aspartat amino transferase; CHD, coronary heart disease; CL, clonazepam; ETH, ethosuximide; LTG, lamotrigine; MELAS, mitochondrial myopathy,
encephalopathy, lactacidosis, stroke; OXC, oxcarbazepine; PB, phenobarbitone; SUL, sultiam; TPM, topiramate.
a Not done during encephalopathy.
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Table 2 VPA-induced encephalopathies without or slight hyperammonemia
Age
(year)
Sex Underlying
disease
Retarded EEG VPA-level
(mg/l)
ASAT U/l,
ALAT U/l,
Amm nia
(gm /l)
(11— 5)
Add.
AED
Outcome
1 52 M Focal epilepsy — Theta-focus 63.6 — Norm l CBZ, PB Recovery after withdrawal
of VPA
2 76 F Cerebri med.
infarct
+ Theta-focus 84.6 — — — Recovery after withdrawal
of VPA
3 77 F Post-haemorrhage
epilepsy
+ Background slowing 140 — — — Recovery after VPA-
reduction
4 28 M Schizenzephaly + — — — Norm l TPM, LEV, CL Recovery after withdrawal
of VPA
5 32 F Epilepsy — Background slowing 75 — Norm l CMZ Recovery after withdrawal
of VPA
6 41 M Epilepsy + Background slowing,
poly-spike-waves
— Normal Norm l PB, PHT Recovery after withdrawal
of VPA
7 63 F Post-haemorrhage
epilepsy
+ Background slowing — 124, 28 — PB, PHT Recovery after withdrawal
of VPA
8 64 M Hypoxic brain
damage
+ Background slowing 95.7 Normal 23 — Recovery after withdrawal
of VPA
9 74 F Primary generalized
epilepsy
— Background slowing 95.2 23, — — — Recovery after withdrawal
of VPA
10 4.5 F IGE — Background slowing 78 Normal Norm l PB Recovery after withdrawal
of VPA
11 2.6 F Bourneville Pringle + Background slowing 143.6 52, 436 68 OXC, LTG, CL Recovery after withdrawal
of VPA
12 72 F Cerebri post. infarct — Delta-focus — Normal 64 — Recovery after withdrawal
of VPA
13 19 M Focal epilepsy — Generalized d-activity 72.1 Normal 69 — Recovery after withdrawal
of VPA
CBZ, carbamazepine; CHD, coronary heart disease; CL, clonazepam; IGE, idiopathic generalized epilepsy; PB, phenobarbitone TPM, topiramate.o
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Figure 1 Age distribution of VPA-induced encephalopa-
thies.receptors2 and a blockade of neuronal sodium chan-
nels.3 VPA also effects a variety of different meta-
bolic pathways and the compositing of membranes.4
Most of the side effects are mild and transient.
However, more serious adverse reactions can occur
such as hepatotoxicity,5 encephalopathy,6 coagula-
tion disorders7 pancreatitis8 and bone marrow sup-
pression.9
Three forms of encephalopathy in children and
adults treated with VPA have been described: ence-
phalopathy as direct toxic effect of VPA, with high
serum levels of VPA but normal ammonia,10 hyper-
ammonemic encephalopathy11 and encephalopathy
with impaired liver function.12 Encephalopathy was
reported as an extremely rare complication of VPA
therapy, described mostly in patients with inborn
errors of metabolism, but also in patients without a
known metabolic defect.13
Several publications showed an increased risk of
encephalopathy when VPAwas combined with topir-
amate.13,14
Direct drug effect on neurotransmitters is gen-
erally considered to be the main mechanism of VPA-
induced encephalopathy.15 VPA may lower gluta-
mine synthesis via inhibition of glutamine synthase,
thus contributing to hyperammonemia.16 Another
possible mechanism is direct neuronal toxicity
induced by increased intracellular concentrations
of glutamate and ammonium in astrocytes17 which
may lead to potential neuronal injury and perhaps
cerebral edema.18 It is not clear, whether changes in
citrullinogenesis or in other steps of the urea cycle
account for the increase of blood ammonia induced
by valproate.19 Up to 20% of asymptomatic patients
treated with VPA may have mild hyperammone-
mia.20
We report 19 patients with VPA-induced encepha-
lopathy in Germany from the years 1994 to 2003,
none of whom had been published previously.
Since 1979, 51 cases of VPA-associated encepha-
lopathy were reported in the literature.5,6,21—34
Additionally, 13 cases of VPA-associated encephalo-
pathy were reported in combination with
TPM.7,13,14,35—37
Methods
We sent a questionnaire asking for side effects of
VPA therapy from 1994 to 2003, to all 1200 members
(Paediatricians, Neurologists) of the ‘‘German Sec-
tion of the International League against Epilepsy’’.
We specially inquired about severe side effects such
as hepatopathy, pancreatitis, encephalopathy and
coagulation disorders. The physicians were also
asked for the anonymisized patient files in orderto obtain details like VPA-dosage, laboratory para-
meters, the history and the outcome of the patients.
Results
In the last 10years altogether19casesofVPA-induced
encephalopathy were reported in Germany by mem-
bers of German Section of the International League
against Epilepsy. We analyzed the medical files of
these 19 patients. Another eight patients were
reported but wewere not able to study the complete
files. These patients were therefore omitted.
Tables 1 and 2 present details of the 19 patients,
divided into two subgroups: patients with encepha-
lopathy and hyperammonemia and patients with
normal serum-ammonia or slight hyperammonemia
(69, 68 and 64 gmol/l).
The average age of the patients was 38.6 years;
the age distribution is shown in Fig. 1.
Eight of the patients were male, 11 female. Ten
patients were mentally retarded, most of them
children with infantile brain damage, only one
had an inborn metabolic disorder (MELAS-syn-
drome). The VPA-treatment was started before
the metabolic disorder was known.
All patients recovered after withdrawal of VPA. A
76-years-old women showed a prolonged onset with
a slow recovery over 4 months. This patient was
transferred to a nursery home when the encephalo-
pathy began, but was able to live on her own again
after the withdrawal of VPA. She additionally suf-
fered from a Parkinson-syndrome, which may
explain the prolonged normalisation.
VPA-induced encephalopathy may also occur at
normal or slightly increased ammonia levels,38 which
was the case in 13 of our patients. Six patients, on the
other hand, showed increased ammonia level. The
average level was 191.2 gmol/l (111—259 gmol/l)
(Table 1).Discussion
VPA-induced encephalopathy is an important and
severe side effect of AED-therapy. In contrast to
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Figure 2 Possible types of VPA-induced encephalopathy.previous publications, not only young children with
metabolic defects were affected in our series, but
also adults.
Nevertheless, neurological disabilities and meta-
bolic disorders were a risk factor for VPA-induced
encephalopathy.
The following four types of VPA-induced ence-
phalopathy have to be distinguished.- (1a) Encephalopathy with normal ammonia in 13
patients in our study, a direct effect on neuro-
transmitters postulated.15- (1b) Encephalopathy with hyperammonemia with-
out liver failure in six patients in this study–—an
inhibition of urea cycle is considered to be the
pathomechanism, but this could not be the only
reason, because some patients show encephalo-
pathy with a moderate hyperammonemia by inhi-
biting the urea cycle, some do not.- (2a) Encephalopathy with hyperammonemia and
liver failure. Within our questionnaire we have
found nine cases of lethal hepatopathies, with
increased ammonia levels (average 271 gmol/l)
and signs of an encephalopathy (fatigue, nausea
and EEG-slowing). Additionally, apathy, EEG-slow-
ing and hyperammonemia was found in 5 of the
16 patients (31%) in the series of Scheffner and
Koenig.39- (2b) Encephalopathy without hyperammonemia
but liver failure: 31 cases of reversible hepato-
toxicity (with and without hyperammonemia).
4/31 cases showed normal ranges of ammonia but
the above described signs of encephalopathy (not
regarded here but in a separate paper) (Fig. 2).
For sure it is by all means possible to have the
same pathophysiological mechanism leading to the
encephalopathy 2a and 2b.
On the other hand, there are patients (up to 20—
50% in the series of Laub, Altunbasak and Ver-
rotti20,40,41) that have a slightly elevated serum
ammonia without clinical abnormalities. This can
be considered an effect of the inhibition of the urea
cycle by VPA. Although, there is still a lack of
evidence to this hypothesis. We do not routinelymeasure ammonia in asymptomatic patients, as
clinical consequences in these patients cannot be
derived but patients and physicians are irritated
without any reason.
From 1979 until now 51 patients with VPA-
induced encephalopathy have been published in
the literature. We found, however, 19 patients only
in Germany in the last 10 years, in opposition to the
statement, that VPA-associated encephalopathy is
an extremely rare side effect. We therefore believe
that the occurrence of this severe side effect is
underestimated as reversible side effects are less
likely to be published.
VPA-induced encephalopathy should also be con-
sidered in patients with rapidly progressing severe
dementia who are treated with valproate. These
patients should receive an EEG and blood tests for
serum ammonia, liver enzymes and VPA-serum-level.
Fortunately all patients with VPA-induced ence-
phalopathy but normal transaminases and normal
coagulation can be expected to recover after with-
drawal or reduction of VPA.References
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